Skip Navigation

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin NSC: 772518 for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Brief Summary


Study Type:

III Identifier:

Study #:
CMH - AALL1732

Start Date:
Mar 17, 2020

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT03959085

View Complete Trial Details & Eligibility at